BIOV Stock Overview A clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. More details
Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
BioVaxys Technology Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for BioVaxys Technology Historical stock prices Current Share Price CA$0.055 52 Week High CA$0.10 52 Week Low CA$0.04 Beta -0.17 1 Month Change -8.33% 3 Month Change -26.67% 1 Year Change -15.38% 3 Year Change -71.05% 5 Year Change n/a Change since IPO -85.53%
Recent News & Updates
New major risk - Market cap size Feb 06 BioVaxys Technology Corp. announced that it expects to receive CAD 1 million in funding Nov 19
New major risk - Financial position Oct 09
New major risk - Market cap size Oct 01
Co-Founder recently sold CA$300k worth of stock Sep 15
New major risk - Shareholder dilution Aug 01 See more updates
New major risk - Market cap size Feb 06 BioVaxys Technology Corp. announced that it expects to receive CAD 1 million in funding Nov 19
New major risk - Financial position Oct 09
New major risk - Market cap size Oct 01
Co-Founder recently sold CA$300k worth of stock Sep 15
New major risk - Shareholder dilution Aug 01
BioVaxys Technology Corp. announced that it expects to receive CAD 0.5 million in funding Jul 25 BioVaxys Technology Corp. announced that it expects to receive CAD 0.5 million in funding Jul 24
New major risk - Market cap size Jul 18
BioVaxys Technology Corp., Annual General Meeting, Aug 15, 2024 Jun 05
New minor risk - Financial data availability Jun 01
BioVaxys Technology Corp. Appoints Christopher Cherry as Chief Financial Officer Apr 30
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMage Apr 03 BioVaxys Technology Corp. announced that it expects to receive CAD 1 million in funding Mar 23
BioVaxys Technology Corp. Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications Mar 05
New major risk - Shareholder dilution Feb 02
BioVaxys Technology Corp. announced that it expects to receive CAD 1.6 million in funding Jan 10 BioVaxys Technology Corp. announced that it expects to receive CAD 1.6 million in funding Jan 09
Less than half of directors are independent Nov 24
10402588 BC Ltd acquired TAETSoftware Corp. Jun 14 Biovaxys Technology Corp. Announces Corporate Secretary Changes
BioVaxys Technology Corp. Announces Results from the Ohio State University Pan-Sarbecovirus Animal Study Dec 18
BioVaxys Announces Successful Test-Run Production of Its Bi-Haptenized Ovarian Cancer Vaccine Dec 02 BioVaxys Technology Corp. announced that it expects to receive CAD 0.75 million in funding Nov 29
Biovaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021 Nov 17
Less than half of directors are independent Nov 16 BioVaxys Technology Corp. announced that it has received CAD 0.405 million in funding Nov 11
BioVaxys Technology Corp. Further Expands Vaccines Intellectual Property Portfolio Sep 29 BioVaxys Technology Corp. announced that it has received CAD 0.335 million in funding Sep 21
BioVaxys Technology Corp Appoints Craig Loverock as Chief Financial Officer Sep 09
BioVaxys Technology Corp. Announces Completed Synthesis of its Pan-Sarbecovirus Vaccine Candidate and Launch of in Vivo Animal Study Sep 07 BioVaxys Technology Corp. announced that it expects to receive CAD 1 million in funding Aug 05
BioVaxys Technology Corp. Announces HCL Sends First Surgically Excised Ovarian Cancer Tumors Jun 16
BioVaxys Technology Corp. Completes Next Phase of BVX-0918 GMP Production for Eu Clinical Study Jun 09
BioVaxys Technology Corp and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program Jun 04
BioVaxys Technology Corp., Annual General Meeting, May 27, 2022 May 07
BioVaxys Technology Corp. Expands the Patent Coverage for Its Cancer Vaccine Platform May 03
Biovaxys Technology Corp. Appoints Anthony Dutton as A Director of the Company May 02
Less than half of directors are independent Apr 27
BioVaxys Technology Corp. Expands Cancer Vaccine Platform Mar 31 BioVaxys Technology Corp. announced that it has received CAD 0.7985 million in funding Mar 01
BioVaxys Technology Corp. Announces Complete Inhibition of ACE-2 Binding Activity of Hapten-Modified SARS-CoV-2 Protein Feb 17 BioVaxys Technology Corp. announced that it expects to receive CAD 1 million in funding Feb 09
BioVaxys Technology Corp. Begins Toxicity Study Ahead of CoviDTH IND Submission Oct 01
BioVaxys Prepares for Study on Reduced ACE2 Binding Capabilities of Hapten-Modified SARS-CoV-2 Proteins Sep 24
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs Sep 15
FDA Provides Necessary Guidance for Biovaxys to Begin Preparation of Ind for Phase I/Ii Clinical Trials of Covidth Jul 24
BioVaxys Receives Positive FDA Response for Pre-Ind Review for CoviDTH Clinical Development Jun 15
BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH(R) Diagnostic Apr 30
BioVaxys Enters Major Bioproduction Agreement With Wuxi Biologics (Hong Kong) Ltd. To Synthesize Proteins For Its SARS-CoV-2 Vaccine And COVID-T™ Immunodiagnostic Programs Mar 16
BioVaxys Expands Technology Platform to Address Emerging SARS-CoV-2 Variants Mar 03
BioVaxys Technology Corp. Announces the Appointment of Kartik Chandran to Its Scientific Advisory Board Feb 23
Biovaxys and Bioelpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-Production Feb 20
BioVaxys Technology Corp. Appoints Shmuel Farhi as Corporate Advisor Feb 16
BioVaxys Technology Corp. and Procare Health Iberia, S.L. Announce Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines Feb 11
BioVaxys Technology Corp. Announces Resignation of Jeremy Poirier as Director Feb 09
New 90-day high: CA$0.45 Feb 09
BioVaxys Technology Corp. announced that it has received $1.1265 million in funding Feb 06 BioVaxys Technology Corp. Announces SARS-CoV-2 Vaccine Candidate BVX-0320 Stimulates Neutralizing Antibodies to Live Covid-19 Virus
Biovaxys Technology Corp. Initiates Clinical Development Program for Covid-T, Novel Diagnostic Platform for Detecting T-Cell Activity Jan 29
BioVaxys Technology Corp. Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program Jan 26
BioVaxys Technology Corp. Vaccine Platform Stimulates Robust T-cell Response Against Viral Antigens Dec 23
BioVaxys Announces 96.4% Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine Nov 18
BioVaxys Technology Corp. Announces Interim Results from Preclincal Study of its SARS-CoV-2 Vaccine Oct 16 Shareholder Returns BIOV CA Pharmaceuticals CA Market 7D -8.3% 5.0% -0.1% 1Y -15.4% -46.9% 17.9%
See full shareholder returns
Return vs Market: BIOV underperformed the Canadian Market which returned 18.4% over the past year.
Price Volatility Is BIOV's price volatile compared to industry and market? BIOV volatility BIOV Average Weekly Movement 17.2% Pharmaceuticals Industry Average Movement 13.4% Market Average Movement 8.6% 10% most volatile stocks in CA Market 18.5% 10% least volatile stocks in CA Market 3.0%
Stable Share Price: BIOV's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: BIOV's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. Its product pipeline includes Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, which is in phase I clinical stage to treat the MAGE protein family member A9 in human cancers.
Show more BioVaxys Technology Corp. Fundamentals Summary How do BioVaxys Technology's earnings and revenue compare to its market cap? BIOV fundamental statistics Market cap CA$15.70m Earnings (TTM ) -CA$3.63m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BIOV income statement (TTM ) Revenue CA$0 Cost of Revenue CA$0 Gross Profit CA$0 Other Expenses CA$3.63m Earnings -CA$3.63m
Last Reported Earnings
Jul 31, 2024
Earnings per share (EPS) -0.013 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -32.6%
How did BIOV perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 13:15 End of Day Share Price 2025/02/07 00:00 Earnings 2024/07/31 Annual Earnings 2023/10/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources BioVaxys Technology Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
